162
Participants
Start Date
November 18, 2019
Primary Completion Date
October 30, 2024
Study Completion Date
November 1, 2024
Voxelotor
All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
Cairo University Hospital, Abu El Rish Hospital, Cairo
Ain Shams University Hospital - Clinical Research Center (MASRI-CRC), Cairo
UPMC Children's Hospital of Pittsburgh, Pittsburgh
Children's National Medical Center, Washington D.C.
Alexandria University Hospital - Clinical Research Center, Alexandria
ECU Physicians, Brody Outpatient Clinic, Greenville
Children's Healthcare of Atlanta Scottish Rite, Atlanta
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Children's Mercy Hospital, Kansas City
Lagos University Teaching Hospital, Lagos
College of Medicine, University of Ibadan, Ibadan
University College Hospital Paediatric Haematology and Oncology Unit, Ibadan
University of Calabar Teaching Hospital, Calabar
Aminu Kano Teaching Hospital, Kano
Barau Dikko Teaching Hospital/Kaduna State University, Kaduna
Zagazig University Hospital, Zagazig
Ain Shams University Hospital - Clinical Research Center (MASRI-CRC), Cairo
Cairo University Hospital, Abu El Rish Hospital, Cairo
American University of Beirut - Medical Center, Beirut
Nini Hospital, Tripoli
University of Calabar Teaching Hospital, Calabar
University College Hospital NHS Foundation Trust, London
Barts Health NHS Trust , The Royal London Hospital, London
Guy's & St Thomas NHS Trust, St Thomas' Hospital, London
Guy'S and St Thomas' Nhs Foundation Trust, London
Lead Sponsor
Pfizer
INDUSTRY